We were delighted to speak with Professor Gerd R. Burmester (Charité – Universitätsmedizin Berlin, Berlin, Germany) around the open label extension studies of sarilumab for the treatment of active rheumatoid arthritis (EXTEND: NCT01146652 and MONARCH: NCT02332590).
The abstract ‘Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies.‘ (ABSTRACT NUMBER: 1690) was presented at the ACR Convergence, 3-9 November 2021.
- In which patients with rheumatoid arthritis (RA) is sarilumab indicated? (0:15)
- What were the aims and design of the analysis of the EXTEND and MONARCH studies? (0:41)
- What were the efficacy and safety findings of this analysis? (1:41)
- How did these findings compare with other studies? (2:48)
- What can we conclude about the long-term efficacy and safety of sarilumab in RA and what questions remain unanswered? (3:20)
Disclosures: Gerd R. Burmester discloses honoraria for lectures and consulting for Sanofi and Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
Share this Video
Related Videos In Rheumatoid Arthritis
Roy Fleischmann, ACR 2021: Efficacy and Safety of Olokizumab plus Methotrexate in a Placebo and Active Controlled Study
Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) discusses the results from the phase 3, head-to-head, randomized, placebo-controlled clinical trial investigating olokizumab in patients with active rheumatoid arthritis inadequately controlled with methotrexate, with a comparator arm of adalimumab. The abstract entitled ‘Efficacy and Safety of Olokizumab in a Phase III Trial […]
Roy Fleischmann, ACR 2021: Safety and Efficacy of Tofacitinib vs TNF Inhibitors in ORAL Surveillance
It was a pleasure to speak with Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) about ORAL Surveillance (NCT02092467). Mandated by the FDA, due to observed increases in lipids and malignancies in patients with RA treated with tofacitinib, this study was designed to investigate the relative risk of tofacitinib compared to […]
Gilles Boire, ACR 2021: A Mindfulness-Based Program to Improve PROs in patients with Rheumatoid Arthritis
It was a pleasure to discuss with Prof. Gilles Boire (Université de Sherbrooke, Québec, Canada) the recent pilot study in which a Mindfulness-Based Stress Reduction (MBSR) program was offered to patients with controlled rheumatoid arthritis but elevated negative PROs. The abstract entitled ‘Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!